Biodesix to market VeriStrat companion test for Aveo’s ficlatuzumab
Biodesix Inc. (multivariate testing in oncology) agreed to market its VeriStrat as a companion diagnostic to cancer company Aveo Pharmaceuticals Inc.’s ficlatuzumab, an anti-hepatocyte growth factor antibody in Phase II for non-small cell lung cancer (NSCLC). VeriStrat is a serum proteomic blood test that stratifies NSCLC patients based on the expected outcome with EGFR tyrosine kinase inhibitor treatment.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.